Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.
You may also be interested in...
Califf Plans US FDA, NIH Collaboration On Postmarket Evidence Generation
NIH Director Nominee Monica Bertagnolli is on board with both agencies working to better determine how approved treatments work in the real-world, FDA Commissioner Robert Califf said.
Novo Nordisk’s Obesity Drug Activities Break UK Rules Again
The company has been found in breach of the UK code once again for its work with pharmacists, although this time Novo Nordisk has escaped the heaviest censure.
Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III
A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.